These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1033 related articles for article (PubMed ID: 23079689)

  • 21. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines for fracture risk assessment and management of osteoporosis in postmenopausal women and men above the age of 50 in Qatar.
    Alam F; Alsaed O; Abdulla N; Abdulmomen I; Lutf A; Al Emadi S
    Arch Osteoporos; 2024 May; 19(1):34. PubMed ID: 38698101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FRAX® based intervention thresholds for management of osteoporosis in Singaporean women.
    Chandran M; McCloskey EV; Thu WPP; Logan S; Hao Y; Tay D; Ang WC; Aung TKK; Choo KS; Ali A; Yan SX; Huang XF; Liu XM; Yong EL; Lekamwasam S
    Arch Osteoporos; 2018 Nov; 13(1):130. PubMed ID: 30456726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
    Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
    Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the 10-year risk of fracture in Italian postmenopausal women using FRAX®: a north Italian multicenter study.
    Pedrazzoni M; Girasole G; Giusti A; Barone A; Pioli G; Passeri G; Palummeri E; Bianchi G
    J Endocrinol Invest; 2011 Dec; 34(11):e386-91. PubMed ID: 21750394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Goal-directed treatment of osteoporosis in Europe.
    Kanis JA; McCloskey E; Branco J; Brandi ML; Dennison E; Devogelaer JP; Ferrari S; Kaufman JM; Papapoulos S; Reginster JY; Rizzoli R
    Osteoporos Int; 2014 Nov; 25(11):2533-43. PubMed ID: 25199574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of pharmacotherapy in postmenopausal osteoporosis: a longitudinal observational study.
    Pluskiewicz W; Adamczyk P; Franek E; Sewerynek E; Wichrowska H; Napiórkowska L; Stuss M; Rozwandowicz A; Drozdzowska B
    Endokrynol Pol; 2019; 70(6):473-477. PubMed ID: 31909456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postmenopausal osteoporosis: fracture risk and prevention.
    Kaunitz AM; McClung MR; Feldman RG; Wysocki S
    J Fam Pract; 2009 Nov; 58(11 Suppl Postmenopausal):S1-6. PubMed ID: 19891943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postmenopausal osteoporosis: another approach to management.
    Cole R
    J Fam Pract; 2010 Jun; 59(6):E1-7. PubMed ID: 20544058
    [No Abstract]   [Full Text] [Related]  

  • 31. ACOG Practice Bulletin N. 129. Osteoporosis.
    Committee on Practice Bulletins-Gynecology, The American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2012 Sep; 120(3):718-34. PubMed ID: 22914492
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
    Ni W; Jiang Y
    Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic management of osteoporosis.
    Fontenot HB; Harris AL
    J Obstet Gynecol Neonatal Nurs; 2014; 43(2):236-45; quiz E20-1. PubMed ID: 24502394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.
    Kim K; Svedbom A; Luo X; Sutradhar S; Kanis JA
    Osteoporos Int; 2014 Jan; 25(1):325-37. PubMed ID: 24114398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    Osteoporos Int; 2017 Aug; 28(8):2485-2494. PubMed ID: 28536737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer's disease-nested case-control study.
    Taipale H; Rysä J; Hukkanen J; Koponen M; Tanskanen A; Tiihonen J; Kröger H; Hartikainen S; Tolppanen AM
    Osteoporos Int; 2019 Jul; 30(7):1481-1489. PubMed ID: 30993395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .
    Meijer WM; Penning-van Beest FJ; Olson M; Herings RM
    Curr Med Res Opin; 2008 Nov; 24(11):3217-22. PubMed ID: 18922215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fracture risk assessment tool (FRAX) and for the diagnosis of osteoporosis in Japanese middle-aged and elderly women: Chiba bone survey.
    Oka R; Ohira M; Suzuki S; Yoshida T; Koide H; Tanaka T; Tatsuno I
    Endocr J; 2018 Feb; 65(2):193-202. PubMed ID: 29151451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging.
    Shevroja E; Reginster JY; Lamy O; Al-Daghri N; Chandran M; Demoux-Baiada AL; Kohlmeier L; Lecart MP; Messina D; Camargos BM; Payer J; Tuzun S; Veronese N; Cooper C; McCloskey EV; Harvey NC
    Osteoporos Int; 2023 Sep; 34(9):1501-1529. PubMed ID: 37393412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.
    Svedbom A; Hadji P; Hernlund E; Thoren R; McCloskey E; Stad R; Stollenwerk B
    Osteoporos Int; 2019 Sep; 30(9):1745-1754. PubMed ID: 31270592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.